Tag: RADIANCE-II
Money-maker or meritable: Is renal denervation out of retirement?
In a paper published in the July 2024 issue of the Journal of Hypertension, Andrew Sharp (University Hospital of Wales and Cardiff University, Cardiff,...
ReCor Medical announces consistent reduction of blood pressure in pooled analysis...
ReCor Medical and its parent company, Otsuka Medical Devices, announced consistent and significant blood pressure-lowering results across a range of patients with uncontrolled hypertension,...
TCT 2022 hears “important data” from renal denervation trials
Findings from the RADIANCE II randomised pivotal trial, presented at the 2022 Transcatheter Cardiovascular Therapeutics meeting (TCT, 16–19 September, Boston, USA), “confirm that ultrasound...
FDA approves RADIANCE-II study of Paradise ultrasound denervation system
The RADIANCE-II study of the Paradise Ultrasound Denervation System (ReCor Medical) for the treatment of hypertension has been approved by the US Food &...
